Tumour Therapy with Radiolabelled Antibodies
1998
The promise of radiolabelled immunoglobulin therapy (RIT) for selective, patient friendly, cancer treatment has not yet been fulfilled. Only patients with haematological malignancies show sizable response rates after RIT. With solid tumours, intravenous administration of radiolabelled antibodies does not provide sufficient tumour targeting. However, intracompartmental administration may solve this problem, particularly if tumour reactive IgM is used.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
84
References
10
Citations
NaN
KQI